From London: Beacon Therapeutics has a phase 3 trial scheduled to read this year for its gene therapy for X-Linked Retinitis Pigmentosa (XLRP)

BiotechTV - News - From London: Beacon Therapeutics has a phase 3 trial scheduled to read this year for its gene therapy for X-Linked Retinitis Pigmentosa (XLRP)